Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety (Anxiety-CBT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02810171
Recruitment Status : Recruiting
First Posted : June 22, 2016
Last Update Posted : January 31, 2019
Sponsor:
Collaborators:
University of Illinois at Chicago
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Kate D. Fitzgerald, University of Michigan

Brief Summary:
Anxiety is among the most prevalent, costly and disabling illnesses and tends emerge early in childhood. Cognitive behavioral therapy (CBT) is the first-line treatment for early life anxiety, but as many as 40% of young patients who receive CBT fail to get better. The proposed study will examine brain changes marking positive response to CBT for anxiety and how these changes may differ in children compared adolescents. By helping us to understand how CBT works, this study will pave the way for new treatments to stop anxiety early.

Condition or disease Intervention/treatment Phase
Anxiety Disorders Social Anxiety Disorder Social Phobia Generalized Anxiety Disorder Separation Anxiety Disorder Specific Phobia Phobia Agoraphobia Panic Disorder Panic Attack Anxiety Behavioral: Cognitive Behavioral Therapy Behavioral: Relaxation Therapy Not Applicable

Detailed Description:

Impairing anxiety affects 33% of the population by adolescence and can become chronic, leading to depression, substance abuse, school-drop out and even suicide. To reduce anxiety and prevent its sequelae, patients must be effectively treated early; yet, the first line intervention, cognitive behavioral therapy (CBT), has a heterogeneous response with 40-60% of treated patients continuing to experience impairment from residual symptoms. The reasons for variability in CBT outcomes remain poorly understood, but individual (including developmental) differences in brain-behavioral targets of CBT may contribute. This proposal addresses two primary questions: 1) Do individual differences in CBT-relevant brain-behavioral functions lead to variation in CBT outcomes? and 2) Does development contribute to this variation? To answer these questions, this study will measure changes in brain and behavior markers of anxiety, before and after CBT, in children and adolescents across traditional, categorical anxiety disorders (e.g., social, generalized and separation anxiety disorders). Given that CBT facilitates control over fear to enable effective regulation, the investigators hypothesize that brain-behavioral markers of fear sensitivity, cognitive regulatory capacity and cognitive regulation of fear will predict and characterize mechanisms of CBT effect. In addition, the investigators hypothesize that these markers will differentially relate to CBT effect, depending on patient age.

Children and adolescents (7.0 - 17.99 years) with clinically impairing anxiety will be randomized to receive CBT or a relaxation control therapy for 12 weeks. Before and after therapy, all participants will receive an MRI scan to see what regions of the brain become active when emotion and concentration tasks are performed and how that activation is changed after CBT.

While the study itself is of parallel design for its data-collection and measurement purpose, it is listed as a partial-crossover design in the IRB-approved protocol because subjects randomized to the relaxation therapy are given the option of receiving 12-weeks of CBT sessions after the relaxation therapy data has been collected. Some limited data will be collected in patients who are initially randomized to relaxation therapy but then opt to crossover to CBT. MRI data will also be collected in healthy youth before and after 12 weeks (but without intervening therapy) to allow the investigators to control for the simple effects of time that may cause brain changes that are not related to therapy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety
Actual Study Start Date : December 2016
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Active Comparator: Cognitive Behavioral Therapy Behavioral: Cognitive Behavioral Therapy
A therapy which teaches patients coping skills to manage anxiety and gradually yet repeatedly exposes patients to anxiety-provoking thoughts and situations until the anxiety habituates/diminishes.
Other Name: CBT

Relaxation Therapy Behavioral: Relaxation Therapy
An active control therapy with minimal effects on anxiety symptoms. If randomized to this therapy, participants will have the option to cross-over to CBT once the relaxation therapy arms has been completed.

No Intervention: No Intervention: Healthy youth only
Healthy control adolescents matched to gender, race and socioeconomic status (SES) with child and adolescent patients with anxiety will be enrolled. These healthy adolescents will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).



Primary Outcome Measures :
  1. Brain function/structure as assessed by Magnetic Resonance Imaging scans [ Time Frame: Baseline and 12-weeks ]
    Pre- to post-CBT changes in functional, connectivity and structural MRI measures of brain networks relevant for anxiety. Brain regions include the amygdala, anterior insula, dorsal anterior cingulate cortex (dACC) and ventrolateral prefrontal cortex (vlPFC). Functional activation and connectivity of these brain regions are assessed using simple computer tasks performed during MRI scanning. Tasks engage threat reactivity, self-regulatory control and the interaction of these processes. Structural connections between regions will be measured using a MRI technique that measures water diffusion in the brain.


Secondary Outcome Measures :
  1. Pediatric Anxiety Rating Scale [ Time Frame: weeks 0, 3, 6, 9, 12 ]
    The Pediatric Anxiety Rating Scale (PARS) is a clinician-administered assessment to rate the severity of anxiety symptoms associated with common DSM-V anxiety disorders (social phobia, separation anxiety disorder, and generalized anxiety disorder) in children. The investigators are looking for decreases in anxiety severity ratings from pre- to post-treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria for all participants (Clinically Anxious and Healthy):

  • Age 7.0 - 17.99 years
  • Parent or guardian able and willing to give informed consent
  • Ability to tolerate small, enclosed spaces

Exclusion criteria for all participants (Clinically Anxious and Healthy)

  • No metals, implants or metallic substances within or on the body (e.g., orthodontic braces)
  • Vision equal to or better than 20/30 on a Snelling chart, with correction if necessary
  • Not currently taking any psychotropic medication or receiving any psychotherapy (stable doses of stimulants allowable for anxiety subjects with comorbid attention deficit hyperactivity disorder) or receiving hormone therapy other than birth control
  • No lifetime diagnoses of psychotic disorder, mental retardation or autism
  • No history of current substance/alcohol abuse/dependence
  • No evidence of suicidal intentions or behaviors in the past 6 months
  • No history of serious medical or neurological illness
  • If post-pubertal female, not pregnant

Additional Inclusion Criteria for Clinically Anxious Participants:

  • Clinically significant anxiety as determined by structured clinical interview
  • Past history of major depressive episodes are allowable
  • Past history substance/alcohol abuse allowable if in remission for at least 1 year
  • Obsessive-compulsive disorder symptoms are acceptable if not the primary source of interference or distress

Additional exclusion criteria for Healthy Participants:

  • No history of past or current mental illness as determined by structured clinical interview

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02810171


Contacts
Layout table for location contacts
Contact: Jennifer Nidetz, M.S.W 734-232-0130 anxiety-cbt-study@med.umich.edu
Contact: Riley Lowe 734-232-0130 anxiety-cbt-study@med.umich.edu

Locations
Layout table for location information
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Claire Morrison    734-232-0130    Anxiety-CBT-Study@med.umich.edu   
Contact: Jennifer Nidetz, M.S.W.    734-232-0130    Anxiety-CBT-Study@med.umich.edu   
Sponsors and Collaborators
University of Michigan
University of Illinois at Chicago
National Institute of Mental Health (NIMH)
Investigators
Layout table for investigator information
Principal Investigator: Kate D. Fitzgerald, M.D. University of Michigan

Layout table for additonal information
Responsible Party: Kate D. Fitzgerald, Associate Professor, Department of Psychiatry, University of Michigan
ClinicalTrials.gov Identifier: NCT02810171     History of Changes
Other Study ID Numbers: HUM00118950
R01MH107419 ( U.S. NIH Grant/Contract )
First Posted: June 22, 2016    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized data will be shared with the National Database for Autism Research (NDAR) and the Research Domain Criteria Database (RDoCdb).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Kate D. Fitzgerald, University of Michigan:
anxiety
social anxiety disorder
generalized anxiety disorder
phobias
fears
worry

Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Anxiety Disorders
Phobic Disorders
Panic Disorder
Phobia, Social
Agoraphobia
Anxiety, Separation
Pathologic Processes
Mental Disorders
Neurodevelopmental Disorders